Interference of modern antibacterials with bacillus Calmette-Guerin viability

Journal of Urology

Volumn 162, Issue 6, 1999, Pages 1959-1962

  Durek, Christoph ^a   Rüsch Gerdes, Sabine ^a   Jocham, Dieter ^a   Böhle, Andreas ^a  

^a NONE

Author keywords

Bladder; Cycloserine; Immunotherapy; Mycobacterium bovis; Neoplasms

Indexed keywords

AMIKACIN; AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BCG VACCINE; CAPREOMYCIN; CARBENICILLIN; CEFACLOR; CEFOXITIN; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; CYCLOSERINE; DOXYCYCLINE; ETHAMBUTOL; ETHIONAMIDE; GENTAMICIN; ISONIAZID; KANAMYCIN; NORFLOXACIN; OFLOXACIN; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TOBRAMYCIN; TRIMETHOPRIM;

ANTIBACTERIAL ACTIVITY; ARTICLE; CELL KILLING; CELL VIABILITY; DRUG EFFECT; HUMAN; IMMUNOTHERAPY; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; RADIOMETRY;

EID: 0345008947     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)68078-0     Document Type: Article

References (27)

1. Lamm, D. L., Crawford, E. D., Blumenstein, B. A., Crissman, J. D., deVere White, R. W., Wolf, M., Lowe, B. A., Sarosdy, M. F., Schellhammer, P. F., Sagalowsky, A., Smith, A. Y., Grossman, H. B., Flanigan, R., Moon, T., Brendler, C. B. and Coltman, C. SWOG 8795.: A randomized comparison of bacillus Calmette-Guérin and mitomycin C prophylaxis in stage Ta and T1 transitional cell carcinoma of the bladder. J. Urol., 149: 282A, 1993.
2. Martinez-Pineiro, J. A., Leon, J., Martinez-Pineiro, L., Fiter, L., Mosteiro, J., Navarro, J. and Matres, M.: Bacillus Calmette-Guérin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J. Urol., 143: 502, 1990.
3. Ratliff, T. L., Palmer, J. O., McGarr, J. A. and Brown, E. J.: Intravesical BCG therapy for murine bladder tumors: Initiation of the response by fibronectin-mediated attachment of BCG. Cancer Res., 47: 1762, 1987.
4. Lamm, D. L., Steg, A., Boccon-Gibod, L., Morales, A., Hanna, M. G., Pagano, F., Alfthan, O., Brosman, S. A., Fisher, H., Jakse, G., Chisholm, G. D., van der Meijden, A. P. M. and Debruyne, F. M. J.: Complications of bacillus Calmette-Guérin immunotherapy: A review of 2602 patients and comparison of chemotherapy complications. In: EORTC Genito-Urinary Group Monograph 6: BCG in Superficial Bladder Cancer. Edited by F. M. J. Debruyne, L. Denis and A. P. M. van der Meijden. New York: Liss, 1989, p. 335.
5. Stassar, M. J. J. G., Vegt, P. D. J., Steerenberg, P. A., van der Meijden, A. P. M., Meiring, H. D., Dessens-Kroon, M. and Geertzen, H. G. M.: Effects of isoniazid (INH) on the BCG-induced local immune response after intravesical BCG therapy for superficial bladder cancer. Urol. Res., 22: 177, 1994.
6. de Boer, E. C., Steerenberg, P. A., van der Meijden, A. P. M., van Klingeren, B., de Jong, W. H., Elgersma, A. and Debruyne, F. M. J.: Impaired immune response by isoniazid treatment during intravesical BCG administration in the guinea pig. J. Urol., 148: 1577, 1992.
7. Lee, T. S. and Crispen, R. G.: Rapid Quantitative Measurement of Drug Susceptibility of Mycobacteria. Chicago: Illinois Institute for Tuberculosis Research, 1973.
8. Lamm, D. L., Riggs, D. R., DeHaven, J. I. and Ting, E.: Reduction of BCG fatal toxicity in mice. J. Urol., part 2, 145: 858, 1991.
9. Rist, N., Canetti, G., Boisvert, H. and LeLirzin, M.: L'Antibiogramme du BCG: Valeur diagnostique de la résistance a la cyclosérine. Rev. Tuberc. Pneumol. Ther., 31: 1060, 1967.
10. DeHaven, J. I., Traynellis, C., Riggs, D. R., Ting, E. and Lamm, D. L.: Antibiotic and steroid therapy of massive systemic bacillus Calmette-Guérin toxicity. J. Urol., 147: 738, 1992.
11. DIN-Norm 58943-8: Empfindlichkeitsprüfung von Tuberkulose-bakterien gegen Chemotherapeutika. Berlin: Beuth Verlag, 1996.
12. Siddiqi, S. H., Libonati, J. P. and Middlebrook, G.: Evaluation of a rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis. J. Clin. Microbiol., 13: 908, 1981.
13. Canetti, G. and Grosset, J.: Anonymous examens bactériologiques en tuberculose. Paris: de la Rivière, 1968.
14. Otten, H., Plempel, M. and Siegenthaler, W.: Übersicht zur Pharmakokinetik der Antibiotika, In: Antibiotika-Fibel. Edited by A. M. Walter and L. Heilmeyer. Stuttgart: Thieme Verlag, pp. 710-721, 1980.
15. Herr, H. W., Pinsky, C. M., Whitmore, W. F., Jr., Sogani, P. C., Oettgen, H. F. and Melamed, M. R.: Long-term effect of intravesical bacillus Calmette-Guérin on flat carcinoma in situ of the bladder. J. Urol., 135: 265, 1986.
16. Shapiro, A., Ratliff, T. L., Oakley, D. M. and Catalona, W. J.: Reduction of bladder tumor growth in mice treated with intravesical bacillus Calmette-Guérin and its correlation with bacillus Calmette-Guérin viability and natural killer cell activity. Cancer Res., 43: 1611, 1983.
17. Kelley, D. R., Ratliff, T. L., Catalona, W. J., Shapiro, A., Lage, J. M., Bauer, W. C. and Haaff, E. O.: Intravesical bacillus Calmette-Guérin-therapy for superficial bladder cancer: effect of bacillus Calmette-Guérin viability on treatment results. J. Urol., 134: 48, 1985.
18. Bartlett, G. L., Kreider, J. W., Purnell, D. M. and Katsilas, D. C.: Augmentation of immunity to line 10 hepatoma by BCG. Comparison of different BCG preparations. Cancer, 46: 488, 1980.
19. Mackaness, G. B., Auclair, D. J. and Lagrange, P. H.: Immunopotentiation with BCG. I. Immune response to different strains and preparations. J. Natl. Cancer Inst., 51: 1655, 1973.
20. Akaza, H., Iwasaki, A., Ohtani, M., Ikeda, N., Niijima, K., Toida, I. and Koiso, K.: Expression of antitumor response. Role of attachment and viability of bacillus Calmette-Guérin to bladder cancer cells. Cancer, 72: 558, 1993.
21. Brosman, S. A.: Bacillus Calmette-Guerin immunotherapy. Techniques and results. Urol. Clin. N. Amer., 19: 557, 1992.
22. Lamm, D. L., van der Meijden, A. P. M., Morales, A., Brosman, S. A., Catalona, W. J., Herr, H. W. and Soloway, M. S.: Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J. Urol., 147: 596, 1992.
23. Beermann, D., Scholl, H., Wingender, W., Förster, D., Beubler, E. and Kukovetz, W. R.: Metabolism of ciprofloxacin in man. In: Proceedings of the First International Ciprofloxacin Workshop. Edited by H. C. Neu and H. Weuta. Leverkusch, Germany: Excerpta Medica, 1986.
24. Lamm, D. L.: Complications of bacillus Calmette-Guerin immunotherapy. Urol. Clin. N. Amer., 19: 565, 1992.
25. Koukol, S. C., DeHaven, J. I., Riggs, D. R. and Lamm, D. L.: Drug therapy of bacillus Calmette-Guerin sepsis. Urol. Res., 22: 373, 1995.
26. van der Meijden, A. P. M., van Klingeren, B., Steerenberg, P. A., de Boer, E. C., de Jong, W. H. and Debruyne, F. M. J.: The possible influence of antibiotics on results of bacillus Calmette-Guérin intravesical therapy for superficial bladder cancer. J. Urol., 146: 444, 1991.
27. Rawls, W. H., Lamm, D. L., Lowe, B. A., Crawford, E. D., Sarosdy, M. F., Montie, J. E., Grossmann, H. B. and Scardino, P.: Fatal sepsis following intravesical Bacillus Calmette-Guérin administration for bladder cancer. J. Urol., 144: 1328, 1990